Mentice AB (publ) receives an order of USD 620,000 for simulation solutions and development services

GOTHENBURG, Sweden, Sept. 23, 2022 /PRNewswire/ --  Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that a leading global healthcare technology company, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, for an order of USD 620,000.

"Working with leading innovative partners, we value the opportunity to collaborate in this space to achieve the ambition to improve healthcare and ultimately the care for patients", says Göran Malmberg, CEO and Group president for Mentice, "this project focusing on our Intracardiac Echocardiography (ICE) set of solutions is a development area for Mentice, where we have over the last couple of years developed the world's leading solutions in this medical area. Our ICE solutions are now used by the majority of the world's leading medtech industry."

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com 

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, on 22 of August 21.30 CEST, 2022. 

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

https://news.cision.com/mentice-ab

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/mentice-ab/r/mentice-ab--publ--receives-an-order-of-usd-620-000-for-simulation-solutions-and-development-services,c3635382

The following files are available for download:

https://mb.cision.com/Main/18275/3635382/1629957.pdf

Release

Cision View original content:https://www.prnewswire.co.uk/news-releases/mentice-ab-publ-receives-an-order-of-usd-620-000-for-simulation-solutions-and-development-services-301631821.html



Veröffentlicht am 23.09.2022

Aktuelle Research Artikel

Rohstoffe

Graphen verändert die Welt und die Argo Graphene Aktie ist ganz vorne dabei

Argo Graphene Solutions Corp. Aktie (WKN: A41C57): Argo Aktie steht für ein Unternehmen, das mit Graphen, einem starken, dünnen und leitfähigen Material, Branchen revolutionieren könnte.
Biotechnologie

BioNxt: Neue Ära der Chemotherapie mit Kursziel 2,50 EUR

BioNxt Solutions Inc. Aktie (WKN: A3D1K3): BioNxt Solutions entwickelt gezielte Krebstherapien und sublinguale Schmelzfilme, um Nebenwirkungen zu reduzieren und Patientenkomfort zu erhöhen.
Rohstoffe

Kursziel 8,55 EUR: Warum Analysten in Rektron großes Potenzial sehen

Rektron Group Inc. Aktie (WKN: A407W8): Rektron Group Inc. ist ein agiler Rohstoffhändler, der sich auf Nachhaltigkeit und digitale Trends konzentriert und in Wachstumsmärkten wie Indien, Vietnam und Afrika expandiert.
Biotechnologie

Radiopharmazeutika: Warum diese Biotech-Aktie in Ihr Depot gehört

Defence Therapeutics Inc. Aktie (WKN: A3CN14): Defence Therapeutics entwickelt mit Accum® eine Plattform, die die intrazelluläre Wirkstofffreisetzung verbessert und in der Biotech-Branche für Krebs und Infektionskrankheiten innovativ ist.
 Ja, ich möchte den Newsletter abonnieren!*
* Sie können sich jederzeit aus dem Newsletter heraus abmelden. Weitere Informationen zum Thema Datenschutz erhalten Sie in unserer Datenschutzerklärung